�鶹��Ѱ�����

As a first-generation college student turned molecular biologist, Brian DeDecker imagines a day when humble soybeans beans, which his family has grown for generations, pack a bounty of therapeutic but hard-to-obtain natural compounds.

VegWorld Magazine—Meati Foods, a �鶹��Ѱ�����Boulder spinout and the producer of delicious animal-free, whole-food protein, this week debuted an evolving chef partnership series coined the “Meati Culinary Collective,” featuring Meati’s mushroom root-based creations as prepared by a diverse roster of celebrated chefs.

GEN—Xalud Therapeutics, a �鶹��Ѱ�����Boulder spinout, is developing a non-viral DNA-delivered therapy platform to treat conditions caused by pathologic inflammation 

New research from �鶹��Ѱ�����Boulder could ultimately pave the way to novel approaches for treating a host of human diseases, from autoimmune disorders like Rheumatoid arthritis and Crohn’s disease to neurodegenerative diseases like Parkinson’s disease.

FDA—Flow imaging software from Theodore W. Randolph's (College of Engineering and Applied Sciences) lab and licensed to SentrySciences to create their ParticleSentryAI product was recently highlighted by the FDA in advancing drug product quality.

TechCrunch—Meati Foods, a �鶹��Ѱ�����Boulder spinout, is closer to full-scale production of its whole-food protein made from the structural fibers of mushrooms, known as mycelium. The company announced Thursday the opening of its production facility,

Forbes—�鶹��Ѱ�����Boulder startup Inscripta, a global leader in genome engineering, is reshaping the image of a synthetic biology company. Biomanufacturing is set to transform many industries by making the products that the world needs cleaner, more

LongPath Technologies Inc.—LongPath, a �鶹��Ѱ�����Boulder startup and monitoring service providing continuous detection and quantification of methane emissions for the oil field, announced the appointment of Sam Cummings as executive vice president for strategy and chief financial officer and Joe Quoyeser as senior vice president and chief commercial officer.

<p>�鶹��Ѱ�����Boulder spinout Inscripta®, a global leader in genome engineering technology, announced the acquisition of two pioneers of synthetic biology—Infinome Biosciences and Sestina Bio, which advance Inscripta’s strategy to develop and

�鶹��Ѱ�����Boulder spinout InDevR Inc, a provider of analytical technologies for vaccines and biotherapeutics, announced that it has raised $9 million in series B financing. Adjuvant Capital has invested $4 million, and bioMérieux $5 million. Together, these investments will support InDevR’s commercial expansion and ongoing development of new reagent kits for its VaxArray® platform.